首页> 外文期刊>The American journal of orthopedics >Current and Future Stem Cell Regulation: A Call to Action
【24h】

Current and Future Stem Cell Regulation: A Call to Action

机译:当前和未来的干细胞监管:行动呼吁

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The orthopedic sports medicine profession experienced a pivotal shift with the acceptance and application of the arthroscope. The next leap forward will hinge on the acceptance, application, and regulation of biologic therapies, and a sentinel event will be the US Food and Drug Administration approval of a stem cell technology. While the arthroscope was developed in the hands of our sports medicine mentors, the current history of biologics has been mostly written by basic scientists. The baby steps of these technologies have involved benchtop laboratory studies and preclinical animal trials, clearly illustrating great potential. Clinical progress has struggled forward but stalled. Regulatory constraints and our inability to establish safety and efficacy are the major hurdles, with disconnect between the basic scientist, clinician, and regulatory bodies to blame. While the development of the arthroscope was barely influenced by governmental regulation, this will control and model the future of stem cell technologies. With current legislation before Congress concerning stem cell regulation, the next steps are dependent upon the clinician's understanding and participation in this regulation.
机译:随着关节镜的接受和应用,骨科运动医学界经历了一个关键的转变。下一步的飞跃将取决于生物疗法的接受,应用和规范,而前哨事件将是美国食品和药物管理局批准的干细胞技术。虽然关节镜是在我们的运动医学导师手中开发的,但当前的生物制剂历史大部分是由基础科学家撰写的。这些技术的婴儿步骤涉及台式实验室研究和临床前动物试验,清楚地表明了巨大的潜力。临床进展艰难,但停滞不前。监管方面的限制以及我们无法建立安全性和有效性是主要的障碍,应归咎于基础科学家,临床医生和监管机构之间的脱节。尽管关节镜的发展几乎不受政府法规的影响,但这将控制和模拟干细胞技术的未来。根据国会有关干细胞调节的现行立法,接下来的步骤取决于临床医生对这种调节的理解和参与。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号